Search Results for: collaboration

OncoArendi Therapeutics Appoints Dr. Adam Gołębiowski, Dr. Zbigniew Zasłona and Agnieszka Rajczuk-Szczepańska to its Management Board  

New members to bring additional scientific, operational and HR expertise  Warsaw, Poland – 31 January 2022 - OncoArendi Therapeutics S.A. (”OncoArendi”; WSE: OAT), a clinical stage biotechnology company that uses its world leading medicinal capabilities to

Read more

OncoArendi Therapeutics Appoints Samson Fung, M.D. as Chief Medical Officer

Dr. Fung to Lead Global Clinical Development, Translational Science and Regulatory Strategies Warsaw, Poland – 27 January 2022 - OncoArendi Therapeutics S.A. (”OncoArendi”; WSE: OAT), a clinical stage biotechnology company that uses its world leading medicinal

Read more

OncoArendi Therapeutics supervisory board welcomes international biopharmaceutical experts: Nancy Van Osselaer, Paul van der Horst and Rafal Kamiński as its new members

OncoArendi Therapeutics supervisory board welcomes international biopharmaceutical experts: Nancy Van Osselaer, Paul van der Horst and Rafal Kamiński as its new members Appointments bring global leadership experience and expertise in drug discovery, as well as clinical

Read more

OncoArendi continues to grow by executing further steps of the strategy and initiates two new drug discovery programs within its existing research platforms

According to the strategy released in March, OncoArendi Therapeutics S.A. (WSE: OAT) expands its existing innovative drug discovery platforms by launching two new programs: CHIT1 SELECTIVE focusing on new therapeutic areas within the chitinase platform and

Read more

OncoArendi executes the strategy for 2021-2025 in the area of R&D platform for developing small molecules modulating RNA function

· On June 16 2021, the Company signed a scientific cooperation agreement with the International Institute of Molecular and Cell Biology in Warsaw (IIMCB) in the field of discovery and development of small molecule drugs modulating

Read more

Drug Candidate OATD-01 may find use in treatment of pulmonary fibrosis in patients who have survived a new coronavirus infection (COVID-19)

Potential effectiveness of OATD-01 in the treatment of pulmonary fibrosis is based on a unique mechanism of inhibiting a new biological target – chitotriosidase 1 (CHIT1)Linking COVID-19 infection to pulmonary fibrosis where CHIT1 plays a role

Read more

New Head of Research (Chief Scientific Officer) at OncoArendi

OncoArendi has recently hired dr. Rafał Kamiński for the position of Chief Scientific Officer. He has acquired broad international experience in discovery and development of innovative small molecule drugs and management of scientific teams from previous

Read more

OncoArendi Therapeutics Gets Listed

OncoArendi Therapeutics S.A., an innovative, clinical stage, biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics for cancer and respiratory diseases, has filed documents with the Financial Supervision Authority, initiating the process aiming for the

Read more

OncoArendi receives a grant of over 7 mln PLN for its lead drug discovery program

 OncoArendi will benefit from over 7 M in public financing within the Innovative Economy Operational Program, Action 1.4: “Support for targeted research projects”. The project, entitled “Selective inhibitors of acidic mammalian chitinase (AMCase) as potential therapy

Read more